NCCN Guidelines and Compendium Updated
NCCN Flash Update distributed November 29, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Chronic Myelogenous Leukemia (CML). These NCCN Guidelines® are currently available as Version 3.2013.
- Bosutinib was added as a treatment option in the following circumstances:
- Chronic phase CML
- For patients with inadequate initial response to prior tyrosine kinase inhibitor (TKI) therapy
- BCR-ABL transcript levels > 10% by QPCR using the International Scale (IS) or < partial cytogenetic response (PCyR) on bone marrow cytogenetics at 3 months
- Less than complete cytogenetic response (CCyR) at 12 and 18 months
- Continuation of therapy for patients (who have been switched to bosutinib as early as 3 months for inadequate initial response to prior TKI therapy) in CCyR 12 months and 18 months or PCyR at 12 months
- Loss of response (increase in BCR-ABL transcript levels or cytogenetic relapse) at 6, 12 and 18 months
- Disease progression to accelerated or blast phase CML on prior TKI therapy
- Follow-up therapy for relapse following allogeneic HSCT
- Omacetaxine was added as a treatment option for patients with chronic phase CML, accelerated phase CML and post-transplant relapse with resistance and/or intolerance to two or more TKIs.
- Treatment options based on mutational status was updated with bosutinib and omacetaxine.
- Toxicity management pages were added for bosutinib and omacetaxine.
- The Discussion Section has been updated to reflect the changes in the algorithm.
For the complete updated versions of the NCCN Guidelines® and the NCCN Compendium®, please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.com.
To access free NCCN Guidelines mobile apps for iPhone and Android, visit NCCN.org/mobile.
Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad and Android. Visit NCCN.org/mobile/tablet.asp.